Clinical trials and analysis on almost 40000 individuals pertaining to statin treatment has led to the identification of two novel genetic variants which have an impact on the response of ‘bad’ cholesterol to statin therapy. Statins are mostly prescribed to those people who suffer from high levels of ‘bad’ cholesterol in their bodies. Statins bring down the levels of the ‘bad’ cholesterol by almost 55% and are also effective in reducing the chances of developing heart diseases. However, in spite of this patient response varies significantly.
This study which was published in Nature Communications was led by the Queen Mary University of London. This study, has been by far the largest till date and it involved data analysis from ten observational studies and 6 randomized clinical trials in order to identify the various genetic forms that have an impact on a patient’s response to statins.
The researcher, along with several other universities all across the globe validated their respective observations in more than 22000 people and came across two new genetic variants which had a significant impact on to what extent bad cholesterol was reduced via statin treatment. According to researchers and professors, this study has marked an important step towards understanding and evaluating the impact and effect of genetic variations on statin response. However, greater research is needed in order to find out how this can be applied in patients who are receiving statins.
According to doctors and scientists, statins are highly effective and are the safest for clinical use. Although most statins share a common purpose, there are some statins which are more effective than other statins in different individuals.